Shigella OMP and LPS Vaccine Adjuvant

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunogenic and immunostimulatory compositions, such as proteosomes, require enhanced containment and may not provide sufficient protection against infections like Shigella, necessitating the development of alternative compositions that are safer and more effective.

Innovation Solution

A composition comprising Shigella outer membrane proteins (OMPs) and Shigella LPS molecules, produced through a process involving cell disruption and centrifugation steps, which serves as an immunogenic and immunostimulatory agent, capable of eliciting an immune response and acting as a vaccine adjuvant.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If proteosomes are used as vaccine adjuvant, then immunogenicity and efficacy are improved, but containment requirements increase to BL-3 level

Engineering Contradiction:

ImproveimmunogenicityVSAvoidcontainment risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention extracts only the beneficial immunogenic components (outer membrane proteins and LPS) from the pathogenic organism, separating them from the harmful elements that would require high-level containment. This is achieved through selective isolation of OMPs and LPS molecules, creating a safe adjuvant that retains immunogenicity without the associated biosafety risks.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention converts potentially harmful pathogenic components into beneficial vaccine adjuvants by using the organism's own outer membrane proteins and LPS as immunostimulatory agents. The harmful pathogen is transformed into a safe source of protective antigens and adjuvants through controlled extraction and purification.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Ease of manufacture

If wild-type strain is used for proteosome preparation, then production is simplified, but safety and containment requirements worsen

Engineering Contradiction:

Improveproduction simplicityVSAvoidsafety risk

Core Design Contradiction:

Ease of manufactureVSObject-affected harmful factors

Solution Approach 1:

The invention uses a disposable, non-replicable approach where the pathogen is used only once to extract its immunogenic components, then destroyed. The OMPs and LPS are isolated and purified, leaving no viable pathogen to propagate, thus eliminating the need for continued high-level containment while maintaining production simplicity.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Adaptability or versatility

If traditional vaccine adjuvants are used, then protection against other infections is provided, but protection against Shigella is insufficient

Engineering Contradiction:

Improvebroad protectionVSAvoidShigella protection

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The invention applies local quality by using Shigella-specific outer membrane proteins and LPS as the adjuvant system, providing targeted protection against Shigella while maintaining the ability to be combined with various antigens for broader vaccine applications. The adjuvant is optimized for Shigella protection while retaining versatility.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The Shigella OMP and LPS composition demonstrates enhanced protective effects, is produced with reduced containment risks, and effectively primes and potentiates adaptive immune responses, offering improved protection against infections.

Implementation Method 1

isolating a fraction comprising an outer membrane protein and LPS, suitably by a process involving one or more centrifugation steps

Methodology Applied

Scientific EffectCentrifugal separation: Centrifugal Separation

Implementation Method 2

a detergent solubilisation step

Methodology Applied

Scientific EffectDetergent solubilisation: Surfactant

Data Source

PatentUS9161975B2Immunogenic composition

Publication Date: 2015.10.20 GLAXOSMITHKLINE BIOLOGICALS SA

AI summary

The present invention relates to the use of a immunogenic or immunostimulatory composition comprising a Shigella outer membrane protein (OMP) and Shigella LPS molecule in medicine and methods for preparing the composition.